HondurasTuberculosis profile
Population  2015 8.1 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.085 (0.085–0.086) 1.1 (1–1.1)
Mortality (HIV+TB only) 0.067 (0.027–0.13) 0.83 (0.33–1.6)
Incidence  (includes HIV+TB) 3.5 (2.9–4.1) 43 (36–51)
Incidence (HIV+TB only) 0.36 (0.23–0.52) 4.5 (2.9–6.5)
Incidence (MDR/RR-TB)** 0.11 (0.058–0.17) 1.4 (0.72–2.1)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.22 (0.14–0.3) 1.2 (0.78–1.6) 1.4 (0.92–1.9)
Males 0.16 (0.1–0.22) 1.9 (1.5–2.4) 2.1 (1.6–2.6)
Total 0.38 (0.27–0.49) 3.1 (2.8–3.4) 3.5 (2.9–4.1)
TB case notifications, 2015  
Total cases notified 2 919
Total new and relapse 2 906
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 88%
          - % pulmonary 89%
          - % bacteriologically confirmed among pulmonary 84%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 83% (71–99)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.04 (0.03–0.06)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 267 10%
          - on antiretroviral therapy 118 44%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  94
(52–140)
Estimated % of TB cases with MDR/RR-TB 2.2% (0.69–3.7) 21% (10–31)  
% notified tested for rifampicin resistance 19% 74% 665
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 16, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 12, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 89% 1 810
Previously treated cases, excluding relapse, registered in 2014 68% 180
HIV-positive TB cases, all types, registered in 2014 63% 256
MDR/RR-TB cases started on second-line treatment in 2013 75% 4
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-09 Data: www.who.int/tb/data